CKM Syndrome Guidelines 2026: What They Mean for MASLD Screening in Gastroenterology

A 51-year-old woman is referred to hepatology for elevated ALT and hepatic steatosis on ultrasound. Her BMI is 29, her waist circumference is 91 cm, and nobody has ever ordered an eGFR or checked her blood pressure trend. Under the framework hepatologists have used for years, she's a routine MASLD workup. Under the guidelines released this month, she may already be a stage 2 or 3 cardiovascular-kidney-metabolic (CKM) syndrome patient - and that changes what happens next.

The first CKM syndrome guidelines, jointly issued by the American Heart Association, American College of Cardiology, American Society of Nephrology, and American Diabetes Association, formalize something gastroenterologists have watched unfold clinically for a decade: metabolic dysfunction–associated steatotic liver disease rarely travels alone. As JAMA's coverage of the guideline explains, the framework helps clinicians diagnose, stage, treat, and monitor CKM syndrome based on the interconnections among metabolic risk factors, chronic kidney disease, and cardiovascular disease, replacing the 2013 obesity guidelines entirely. For CKM syndrome and MASLD screening in particular, the practical question for GI clinicians isn't whether the liver matters - it's whether hepatology's workup now needs to include kidney and cardiovascular staging it has traditionally left to other specialties.

Case in point

The patient above returns for her follow-up. Her transaminases have improved slightly on lifestyle counseling, and her ultrasound still shows steatosis without obvious cirrhotic features. This time, her workup includes eGFR (78 mL/min/1.73m²), UACR (42 mg/g - mildly elevated), and a blood pressure average of 134/86.

Run through the PREVENT calculator, her 10-year cardiovascular risk lands at 9%. That crosses the 7.5% threshold the guidelines use to inform whether to initiate a GLP-1-based therapy or an SGLT2 inhibitor for CKM syndrome - not as a liver-directed decision, but as a cardiometabolic one that happens to also help her steatosis. She's staged as CKM 2 going on 3, and that stage, not her ALT trend, is now the number driving the conversation about escalation.

Screening and Referral Triggers Gastroenterologists Should Adopt

Three additions to a standard MASLD intake bring a hepatology visit in line with the new guideline, without requiring a cardiology consult for every patient.

First, waist circumference belongs in the chart alongside BMI. The guidelines set abdominal obesity thresholds at 88 cm or greater for women and 102 cm or greater for men, with lower thresholds for patients of Asian ancestry. Second, eGFR and, where indicated, UACR should be added to the standard MASLD panel rather than deferred to primary care - kidney disease often goes unrecognized until later stages despite now being treatable earlier. Third, a PREVENT score above 7.5% or 20% (the stage 3 threshold) is a referral trigger, not just a documentation exercise - it's the point at which cardiology or a structured GLP-1/SGLT2 pathway should enter the conversation.

None of this requires the gastroenterologist to manage cardiovascular risk directly. The full CKM Health guideline in Circulation explicitly favors team-based care with a coordinating point person, noting that clinicians already treating these patients can often fill that role. For a MASLD patient already in a hepatology clinic every six months, that coordinator can reasonably be you.

A frequently overlooked point

The instinct in hepatology has been to treat MASLD as the index diagnosis and everything else as a comorbidity list. The CKM framework inverts that: obesity and its metabolic consequences are the root process, and MASLD is one downstream expression of it, not the anchor. A patient staged purely on liver fibrosis risk (say, a low FIB-4) can still be CKM stage 3 on the strength of subclinical coronary calcium or a high PREVENT score - numbers a liver-focused workup will never surface. This distinction matters even more for the lean phenotype discussed in our post on cryptogenic steatotic liver disease in lean patients, where the absence of classic cardiometabolic risk factors can mask real CKM-relevant risk rather than rule it out. Fibrosis staging and CKM staging are two different axes measuring two different futures for the same patient.

Bottom line for clinical practice

• Add eGFR to every MASLD workup, and add UACR once a patient has any second metabolic risk factor - most MASLD patients qualify.

• Calculate a PREVENT score before deciding on GLP-1 or SGLT2 escalation; a 10-year CVD risk ≥7.5% is the guideline's own threshold for starting therapy.

• Document waist circumference at every visit, using the lower Asian-ancestry thresholds where applicable - BMI alone under-detects visceral risk.

• Treat a PREVENT-CVD score ≥20% as a stage 3 flag warranting cardiology or nephrology referral, not just a note in the chart.

• Don't assume a reassuring fibrosis score means reassuring CKM staging - check both independently, especially in lean or atypical presentations.

Next time a MASLD case in your clinic raises a CKM staging question - whether a PREVENT score changes the therapy conversation, or whether a UACR result should trigger referral - walk GastroAGI through the specifics. It returns a guideline-anchored answer in seconds, built for exactly this kind of cross-specialty decision